Bain Capital Life Sciences Investors, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001703031
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2023 · 27 positions · Total reported value $1.04B · Top-10 concentration 81.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 33.3% · 3 new · 3 cut · 2 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q4 2023 13F filing, Bain Capital Life Sciences Investors, LLC disclosed 27 equity positions with a combined reported value of $1.04B. The filing implies a focused portfolio: its ten largest positions account for 81.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2023 were NUVL ($263.25M), NAMS ($116.99M), PHVS ($109.52M). By sector, the heaviest allocations are Health Care 67.5%, Industrials 1.2%. Versus the prior quarter, allocation shifted toward Health Care (+9.5pp) and away from Industrials (-0.6pp), Other (-8.9pp).
Versus the prior quarter, Bain Capital Life Sciences Investors, LLC opened 3 new positions, trimmed 3 and fully exited 2, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 76% of names.
The largest new positions opened in Q4 2023 were MDGL ($75.11M), RVMD ($31.90M).
Of the 2 positions fully exited versus the prior quarter, the largest were SWTX ($71.24M), CRNX ($37.93M), EQRX ($22.21M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2023)
- MDGL MADRIGAL PHARMACEUTICALS INC · $75.11M
- RVMD REVOLUTION MEDICINES INC · $31.90M
Fully Exited (vs previous quarter)
Insider Transactions (Form 4)
Latest Bain Capital Life Sciences Investors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-04-30 | Sell | Heartflow, Inc. | 56,224 | $30.05 | SEC filing |
| 2026-04-30 | Sell | Heartflow, Inc. | 892,533 | $29.18 | SEC filing |
| 2026-04-29 | Sell | Heartflow, Inc. | 797,133 | $29.37 | SEC filing |
| 2026-04-28 | Sell | Heartflow, Inc. | 254,110 | $30.51 | SEC filing |
| 2026-04-20 | Buy | Kailera Therapeutics, Inc. | 1,562,500 | $16.00 | SEC filing |
| 2026-04-20 | Conversion | Kailera Therapeutics, Inc. | 4,145,768 | — | SEC filing |
| 2026-04-20 | Conversion | Kailera Therapeutics, Inc. | 16,875,000 | — | SEC filing |
Fund Profile
Bain Capital Life Sciences Investors, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 21 positions worth $1.68B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 21 positions · $1.68B reported value (Q2 2026)
- Top 10 holdings = 87.9% of reported value
- Largest position: KLRA (KAILERA THERAPEUTICS INC) at 29.6%
- Average position size: $80.10M
Sector Tilt
- Health Care 99.0%
- Industrials 0.9%
- Materials 0.1%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 2 new, 2 added, 7 reduced, 1 exited
- 10 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
3.58M | $263.25M | 25.23% | Hold | |
| 2 |
|
10.47M | $116.99M | 11.21% | Hold | |
| 3 |
|
3.90M | $109.52M | 10.50% | Reduce | |
| 4 |
|
1.33M | $76.97M | 7.38% | Hold | |
| 5 |
|
324.62K | $75.11M | 7.20% | New | |
| 6 |
|
14.23M | $66.89M | 6.41% | Hold | |
| 7 |
|
2.00M | $45.40M | 4.35% | Hold | |
| 8 |
|
8.06M | $36.60M | 3.51% | Add | |
| 9 |
|
1.11M | $31.90M | 3.06% | New | |
| 10 |
|
2.89M | $28.64M | 2.75% | Hold | |
| 11 |
|
400.20K | $25.07M | 2.40% | Reduce | |
| 12 |
|
2.75M | $21.42M | 2.05% | Add | |
| 13 |
|
8.66M | $20.10M | 1.93% | Hold | |
| 14 |
|
3.13M | $19.22M | 1.84% | Hold | |
| 15 |
|
1.82M | $18.81M | 1.80% | Hold | |
| 16 |
|
1.43M | $15.56M | 1.49% | Hold | |
| 17 |
|
16.92M | $14.18M | 1.36% | Add | |
| 18 |
|
3.00M | $9.69M | 0.93% | Hold | |
| 19 |
|
1.64M | $9.28M | 0.89% | Hold | |
| 20 |
|
1.94M | $7.63M | 0.73% | Hold | |
| 21 |
|
2.49M | $7.58M | 0.73% | Hold | |
| 22 |
|
8.43M | $6.24M | 0.60% | Hold | |
| 23 |
|
2.00M | $5.98M | 0.57% | Hold | |
| 24 |
|
1.33M | $5.69M | 0.55% | Reduce | |
| 25 |
|
3.50M | $3.67M | 0.35% | Add | |
| 26 |
|
2.81M | $1.54M | 0.15% | Hold | |
| 27 |
|
100.00K | $313.00K | 0.03% | Hold | |
FAQ
What did Bain Capital Life Sciences Investors, LLC buy in 2023-Q4?
In its 2023-Q4 13F filing, Bain Capital Life Sciences Investors, LLC reported 27 equity positions worth $1.04B in aggregate; its largest disclosed positions were NUVL ($263.25M), NAMS ($116.99M), PHVS ($109.52M).
How large is Bain Capital Life Sciences Investors, LLC's portfolio?
Bain Capital Life Sciences Investors, LLC reported $1.04B of long equity holdings across 27 positions as of 2023-Q4. Top-10 holdings account for 81.6% of reported value.
What is Bain Capital Life Sciences Investors, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.